Last reviewed · How we verify
Beechwood Creosote (creosote)
Beechwood Creosote (generic name: creosote) is a Small molecule drug developed by Lin Jiacheng. It is currently in Phase 1 development. Also known as: oily liquid obtained by distillation of wood tar.
Beechwood Creosote is a small molecule compound that works by interacting with cellular targets to produce a therapeutic effect.
Beechwood Creosote has been studied in clinical trials for the treatment of periapical diseases, specifically in combination with a triple antibiotic paste. According to its chemical properties, Beechwood Creosote is a category of carbonaceous chemicals used as preservatives or antiseptics.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | creosote |
|---|---|
| Also known as | oily liquid obtained by distillation of wood tar |
| Sponsor | Lin Jiacheng |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Mechanism of action
Imagine your body's cells are like a city with many different buildings. Creosote is like a key that unlocks a specific building, allowing it to function properly. This can help to restore balance and health to the city, but more research is needed to understand exactly how it works.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beechwood Creosote CI brief — competitive landscape report
- Beechwood Creosote updates RSS · CI watch RSS
- Lin Jiacheng portfolio CI
Frequently asked questions about Beechwood Creosote
What is Beechwood Creosote?
How does Beechwood Creosote work?
Who makes Beechwood Creosote?
What is the generic name of Beechwood Creosote?
Is Beechwood Creosote also known as anything else?
What development phase is Beechwood Creosote in?
Related
- Manufacturer: Lin Jiacheng — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: oily liquid obtained by distillation of wood tar
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing